| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 42.158 | 39.673 | 36.353 | 60.057 | 62.048 | 15.191 | 29.640 | 58.364 | 48.764 | 57.785 |
| Total Income - EUR | 48.962 | 39.726 | 36.379 | 60.151 | 62.181 | 20.382 | 29.642 | 58.367 | 49.777 | 57.794 |
| Total Expenses - EUR | 47.278 | 57.744 | 27.828 | 55.105 | 48.617 | 24.398 | 23.499 | 37.882 | 36.325 | 51.230 |
| Gross Profit/Loss - EUR | 1.684 | -18.018 | 8.552 | 5.045 | 13.564 | -4.017 | 6.142 | 20.485 | 13.452 | 6.564 |
| Net Profit/Loss - EUR | 215 | -18.480 | 7.905 | 4.444 | 12.944 | -4.577 | 5.253 | 18.926 | 12.982 | 6.015 |
| Employees | 3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Apotrans Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 19.919 | 7.849 | 19.366 | 13.567 | 9.480 | 3.924 | 1.735 | 1.149 | 29.421 | 51.947 |
| Current Assets | 8.046 | 3.838 | 8.740 | 20.722 | 16.231 | 14.112 | 14.114 | 33.358 | 17.859 | 26.985 |
| Inventories | 814 | 321 | 0 | 133 | 0 | 522 | 0 | 0 | 0 | 0 |
| Receivables | 6.156 | 1.985 | 2.633 | 3.047 | 3.999 | 6.702 | 4.526 | 7.805 | 5.548 | 7.876 |
| Cash | 1.076 | 1.532 | 6.107 | 17.542 | 12.232 | 6.888 | 9.589 | 25.553 | 12.311 | 19.109 |
| Shareholders Funds | -49.974 | -67.922 | -58.868 | -53.279 | -39.304 | -43.136 | 12.601 | 31.566 | 44.453 | 50.219 |
| Social Capital | 45 | 67 | 66 | 129 | 126 | 124 | 49.648 | 49.802 | 49.651 | 49.374 |
| Debts | 77.940 | 79.609 | 86.973 | 87.569 | 65.015 | 61.172 | 3.248 | 2.940 | 2.828 | 28.713 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
4931
|
|||||||||
Comments - Apotrans Srl